Next week the diabetes world will gather in Lisbon for EASD and one of the most pressing questions is when will we hear something on a product that has done very well in Europe. Sources have been telling Diabetic Investor that we could be soon be hearing from Abbott (NYSE: ABT) and the FDA’s decision on Libre. A decision that could at EASD which is ironic as the Libre has been approved in Europe for some time and has exceeded everyone’s expectations.
Since the FDA does not reveal much we can only speculate as to why this process . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.